Home › Trials › NCT06824818
Clinical trial Recruiting at 1 site Interventional Ages 70 and up Men only

Stopping prostate cancer hormone injections early in older men

Official title: A Feasibility Trial of LHRH Agonist Discontinuation in Elderly Prostate Cancer Patients

Run by University of Chicago · NCT06824818 · Data updated 2026-11-12

This trial tests whether men aged 70 and older who have been on LHRH agonists for more than three years can safely stop the injections while being monitored with regular testosterone testing.

More Prostate Cancer trials

Quick facts

Study typeInterventional
Ages70 Years and up
SexMen only
Enrollment155 (estimated)
SponsorUniversity of Chicago
Academic / other
Drugs / interventionschemotherapy
Locations2 sites (Chicago, Illinois and 1 other locations)
StatusRecruiting
StartedJune 2026
Main results expectedDecember 2026
Study endsJune 2027
Registry record updatedOctober 1, 2025
Trial IDNCT06824818 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal participants are men aged 70 or older with prostate cancer who have been on continuous LHRH agonist therapy for more than three years, have a baseline testosterone under 20 ng/ml, and have ECOG performance status 0–2.

Probably not a fit

Patients with rising PSA or other evidence of active disease, detectable or recovering testosterone levels, recent chemotherapy or Lu-PSMA without favorable prognosis, those younger than 70, or those with less than three years of LHRH therapy are less likely to benefit from stopping treatment.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Men 70 years or older who have received continuous LHRH agonist therapy for over three years and have a baseline testosterone below 20 ng/ml will discontinue their LHRH injections and be followed with scheduled testosterone measurements and clinical checks. Eligible participants must have an ECOG performance status of 0–2 and generally no prior chemotherapy or Lu-PSMA unless life expectancy and clinical context are favorable. The study team hypothesizes that long-term androgen ablation may produce permanent castration in some elderly men, making ongoing injections unnecessary. The trial is conducted at University of Chicago Medicine and the University of Illinois at Chicago with close monitoring for testosterone recovery and clinical signs of cancer activity.

Why it matters

Potential benefit: If successful, older patients could avoid ongoing hormone injections, reducing side effects, clinic visits, and costs while maintaining cancer control.

How similar studies have gone: Intermittent androgen-deprivation strategies have shown feasibility in other contexts, but permanently stopping long-term LHRH therapy specifically in elderly patients is relatively novel and not widely proven.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Prostate cancer with \>3 years of LHRH agonist therapy.
* Age ≥70 years.
* ECOG performance status ≤2
* Baseline testosterone of \< 20 ng/ml
* No prior chemotherapy or Lu-PSMA (unless survival predictions are favorable).
* Ability to understand and sign informed consent.

Exclusion Criteria:

* none

Where it's running

  • The University of Illinois at Chicago (UIC)
    Chicago, Illinois, United States     Recruiting
  • UChicago Medicine Comprehensive Cancer Center
    Chicago, Illinois, United States     Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Prostate Cancer 1464University of Chicago 1046
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.